ANTIHYPERTENSIVE EFFICACY OF CHRONOPHARMACOTHERAPEUTICAL APPROACH TO ARTERIAL HYPERTENSION IN POST TRANSIENT ISCHEMIC ATTACK PATIENTS

Aim. To assess antihypertensive efficacy of various 24-hour regimens of antihypertensive drugs prescription and the influence on 24-hour profile of blood pressure (BP) and aortic pressure, in systemic hypertension patients post transient ischemic attack.

Material and methods. Totally, 174 patients were included, with grade 1-2 hypertension and previous non-effective treatment; who during the previous 4 weeks had transient ischemic attack. All patients were randomized to 3 groups according to the treatment variant: group 1 (n=59) — valsartan 160 mg and thiazide-like diuretic in the morning, group 2 (n=58) — thiazide-like diuretic in the morning and valsartan 160 mg at bedtime, group 3 (n=57) — thiazide-like diuretic in the morning and valsartan 80 mg b.i.d. (morning and bedtime). At baseline and in 12 months of therapy all patients underwent BP monitoring (ABPM) with assessment of mean 24 hour, daytime, nocturnal systolic BP (SBP) and diastolic BP (DBP), mean pulse pressure, time index of hypertension, SBP and DBP variability at daytime and at night, prominence and velocity of morning SBP and DBP raise, heart rate, central aortic pressure (CAP): SBP and DBP in aorta, variability of SBP and DBP in aorta, pulse BP in aorta, augmentation index in aorta, pulse pressure amplification, ejection period duration, efficacy index of subendocardial blood flow. Valsacor (KRKA, Slovenia) was included in the study as valsartan.

Results. In 12 weeks of fixed combination therapy, the target levels of BP were registered: in group 1 — 43 patients (72,9%), group 2 — 48 (82,7%), group 3 — 55 (96,4%). Reached target BP was more common in b.i.d. intake of valsartan (group 3) comparing to group 1 (p=0,001) and group 2 (p=0,03). Statistically significant positive shifts of ABPM and CAP values were registered in all three regimens. However, in group 2 there was significantly more prominent decrease of the main parameters of ABPM and CAP, than in group 1. Valsartan two times daily (group 3) led to more prominent (p<0,05) improvement of ABPM and CAP value comparing to any variant of its once per day usage (group 1 and 2). In 12 months of treatment, there was a significant (p<0,05) increase in all groups of patients with normalized 24 hour BP profile (“dipper”): in group 1 — 28 (65%), group 2 — 37 (77%), group 3 — 48 (87%). Normalized 24 hour BP trend was registered more commonly in the group 3 patients comparing to those of groups 1 and 2. The differences in the number of “dipper” patients were significant between groups 3 and 1 (p=0,01).

Conclusion. The study showed that b.i.d. or bedtime valsartan intake in combination with diuretic leads to more prominent improvement of the main ABPM and CAP parametes in comparison with the drug intake in the morning, in patients with transient ischemic attack. Two times daily intake of valsartan leads significantly (p<0,05) to normalization of 24 hour BP profile in most patients (87%) and more prominent improvement of the main ABPM, CAP values comparing to once per day morning or evening intake of the drug.

chronopharmacotherapy, ambulatory blood pressure monitoring, central aortic pressure, arterial hypertension, combination antihypertensive therapy, transient ischemic attack

1. Sumin AN, Kolmykova YuA, Kukhareva IN, et al. Annual prognosis in patients with acute impairment of cerebral circulation: the role of the pathological ankle-brachial index. Rational pharmacotherapy in cardiology 2016; 12 (6): 638-44. (in Russ.) Сумин А.Н., Колмыкова Ю.А., Кухарева И.Н. и др. Годовой прогноз у больных с острым нарушением мозгового кровообращения: роль патологического лодыжечно-плечевого индекса. Рациональная фармакотерапия в кардиологии 2016; 12 (6): 638-44. DOI: 10.20996/1819-6446-2016-12-6-638-644.

2. Maier O, Menze BH, von der Gablentz J, et al. ISLES 2015 — A public evaluation benchmark for ischemic stroke lesion segmentation from multispectral MRI. Med Image Anal 2016; 35: 250-69. DOI: 10.1016/j.media.2016.07.009.

3. Kolokolov OV, Kolokolova AM, Lukina EV. Transient ischemic attack: management tactics and antiplatelet therapy for the prevention of cerebral infarction. RMZ 2013; 10: 532. (in Russ.) Колоколов О.В., Колоколова А.М., Лукина Е.В. Транзиторная ишемическая атака: тактика ведения больных и антитромбоцитарная терапия с целью профилактики инфаркта головного мозга. РМЖ 2013; 10: 532.

4. Parfenov VA. Transient ischemic attacks. RMZ 2001; 25: 1174-7. (in Russ.) Парфенов В.А. Транзиторные ишемические атаки. РМЖ 2001; 25: 1174-7.

5. Chazova IE, Zhernakova YuV, Shalnova SA, et al. The prevalence of risk factors for the development of cardiovascular diseases in the Russian population of patients with arterial hypertension. Kardiologiia 2014; 10: 4-12. (in Russ.) Чазова И.Е., Жернакова Ю.В., Шальнова С.А. и др. Распространенность факторов риска развития сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология 2014; 10: 4-12. DOI: 10.18565/cardio.2014.10.4-12.

6. Roman MJ, Okin PM, Kizer JR, et al. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens 2010; 28 (2): 384-8. DOI: 10.1097/HJH.0b013e328333d228.

7. Liu Y, Ushijima K, Ohmori M, et al. Chronopharmacology of angiotensin II-receptor blockers in stroke-prone spontaneously hypertensive rats. J Pharmacol Sci 2011; 115 (2): 196-204. DOI: 10.1254/jphs.10284FP.

8. Skibitsky VV, Kiselev AA, Fendrikova AV. The effectiveness of combination antihypertension therapy with considering the phenomenon of salt-sensitivity in patients with uncontrolled arterial hypertension and diabetes mellitus type 2. Problems of Women’s Health 2016; 11 (4): 15-24. (in Russ.) Скибицкий В.В., Киселев А.А., Фендрикова А.В. Эффективность комбинированной антигипертензивной терапии с учетом солечувствительности пациентов с неконтролируемой артериальной гипертонией и сахарным диабетом 2 типа. Проблемы женского здоровья 2016; 11 (4): 15-24.

9. Smolensky MH, Hermida RC, Ayala DE, Portaluppi F. Bedtime hypertension chronotherapy: concepts and patient outcomes. Curr Pharm Des 2015; 21 (6): 773-90. DOI: 10.2174/1381612820666141024150542.

10. Hermida RS, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005; 23: 1913-22. DOI:10.1097/01.hjh.0000182522.21569.c5Issn.

11. Hermida RS, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 2005; 22: 755-76. DOI: 10.1080/07420520500180488.

12. Ushijima K, Nakashima H, Shiga T, et al. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning. J Pharmacol Sci 2015; 127 (1): 62-8. DOI: 10.1016/j.jphs.2014.09.004.

13. Mazzolai L, Daven V, Centeno C, et al. Assessment of angiotensin II receptor blockade in humans using a stan dardized angiotensin II receptorbinding assay. Am J Hypertens 1999; 12 (12): 1201-8.

14. Leonova MV. Clinical pharmacology of AT II receptor antagonists: valsartan features. Medical advice 2014; 17: 66-71. (in Russ.) Леонова М.В. Клиническая фармакология антагонистов рецепторов АТ II: особенности валсартана. Медицинский совет 2014; 17: 66-71.

15. Smolenskya MH, Hermidab RC, Reinbergc A, et al. Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention. Chronobiology International 2016; 33 (8): 943-1128. DOI: 10.1080/07420528.2016.1184678.

16. Nedogoda SV, Smirnova VO, Barykina IN, et al. The effect of melatonin therapy on endothelial function, blood pressure and vascular stiffness in patients with metabolic syndrome and sleep disorders. Arterial hypertension 2017; 23 (2): 150-9. (in Russ.) Недогода С.В., Смирнова В.О., Барыкина И.Н. и др. Влияние терапии препаратом мелатонина на функцию эндотелия, артериальное давление и сосудистую жесткость у пациентов с метаболическим синдромом и нарушениями сна. Артериальная гипертензия 2017; 23 (2): 150-9. DOI: 10.18705/1607-419X-2017-23-2-150-159

17. Klingbeil AU, John S, Schneider MP et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16: 123-8.

18. Ostroumova OD, Kochetkov AI, Lopukhina MV. The vascular stiffness in patients with arterial hypertension: the potential for antihypertensive therapy. Systemic hypertension 2016; 13 (2): 17-23. (in Russ.) Остроумова О.Д., Кочетков А.И., Лопухина М.В. Сосудистая жесткость у больных артериальной гипертензией: возможности антигипертензивной терапии. Системные гипертензии 2016; 13 (2): 17-23.